Glow-in-the-Dark antibody could help surgeons spot prostate cancer
NCT ID NCT02048150
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identify cancerous tissue during the operation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-PSMA monoclonal antibody MDX1201-A488
- What this could lead to
- If it works, this could help surgeons see prostate cancer more clearly during surgery, potentially leading to more complete tumor removal.
- What could go wrong
- This is a very early, small trial with only 7 people, so results may not apply widely. The imaging technique may not improve outcomes or could miss some cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- Glowing dye could light up hidden lymph nodes in prostate cancer surgery
- AI coaches doctors on cancer risk talks